Recursion Pharmaceuticals Inc (RXRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.99B
Last updated: Nov 17, 2026 at 11:06 AM ET
Recursion Pharmaceuticals Inc (RXRX) Earnings: Report Dates and Results
Recursion Pharmaceuticals (RXRX) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Recursion Pharmaceuticals reported EPS of -$0.22, above the -$0.24 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RXRX has an expected report date of Feb 23, 2027.
RXRX Earnings Call
The latest RXRX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, RXRX beat 9, missed 12 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $18.55M, up 258.8% from $5.17M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.22 | -$0.24 | -$0.25 - -$0.20 | +8.33% | Beat | N/A | 6 | 0 up, 1 down | Nov 2, 2026 | $18.55M |
| Jun 30, 2026 | -$0.25 | -$0.23 | -$0.26 - -$0.20 | -8.70% | Miss | N/A | 5 | 2 up, 0 down | Aug 5, 2026 | $7.67M |
| Mar 31, 2026 | -$0.22 | -$0.26 | -$0.30 - -$0.20 | +15.38% | Beat | N/A | 7 | 0 up, 1 down | May 6, 2026 | $6.47M |
| Dec 31, 2025 | -$0.21 | -$0.30 | -$0.41 - -$0.21 | +30.00% | Beat | N/A | 6 | 1 up, 0 down | Feb 25, 2026 | $35.54M |
| Sep 30, 2025 | -$0.36 | -$0.38 | -$0.45 - -$0.31 | +5.26% | Beat | N/A | 6 | 0 up, 1 down | Nov 5, 2025 | $5.17M |
| Jun 30, 2025 | -$0.41 | -$0.35 | -$0.40 - -$0.29 | -17.14% | Miss | N/A | 6 | 0 up, 1 down | Aug 5, 2025 | $19.22M |
| Mar 31, 2025 | -$0.50 | -$0.52 | -$0.80 - -$0.39 | +3.85% | Beat | N/A | 5 | 0 up, 3 down | May 5, 2025 | $14.74M |
| Dec 31, 2024 | -$0.53 | -$0.42 | -$0.70 - -$0.29 | -27.16% | Miss | N/A | 7 | 1 up, 1 down | Feb 28, 2025 | $4.55M |
| Sep 30, 2024 | -$0.34 | -$0.33 | -$0.40 - -$0.28 | -3.03% | Miss | N/A | 7 | 0 up, 0 down | Nov 6, 2024 | $26.08M |
| Jun 30, 2024 | -$0.40 | -$0.38 | -$0.43 - -$0.35 | -5.26% | Miss | N/A | 6 | 1 up, 0 down | Aug 8, 2024 | $14.42M |
| Mar 31, 2024 | -$0.39 | -$0.43 | -$0.46 - -$0.39 | +9.30% | Beat | N/A | 6 | 0 up, 0 down | May 9, 2024 | $13.79M |
| Dec 31, 2023 | -$0.42 | -$0.45 | -$0.59 - -$0.30 | +6.67% | Beat | N/A | 8 | 0 up, 0 down | Feb 27, 2024 | $10.89M |
| Sep 30, 2023 | -$0.43 | -$0.39 | -$0.43 - -$0.30 | -10.26% | Miss | N/A | 6 | 0 up, 0 down | Nov 9, 2023 | $10.53M |
| Jun 30, 2023 | -$0.38 | -$0.37 | -$0.40 - -$0.35 | -2.70% | Miss | N/A | 7 | 0 up, 0 down | Aug 8, 2023 | $11.02M |
| Mar 31, 2023 | -$0.34 | -$0.35 | -$0.39 - -$0.32 | +2.86% | Beat | N/A | 5 | 0 up, 0 down | May 8, 2023 | $12.13M |
| Dec 31, 2022 | -$0.30 | -$0.24 | -$0.45 - -$0.08 | -25.00% | Miss | N/A | 4 | 0 up, 0 down | Feb 27, 2023 | $13.68M |
| Sep 30, 2022 | -$0.35 | -$0.38 | -$0.43 - -$0.35 | +7.89% | Beat | N/A | 4 | 0 up, 0 down | Nov 8, 2022 | $13.16M |
| Jun 30, 2022 | -$0.38 | -$0.37 | N/A | -2.70% | Miss | N/A | N/A | 0 up, 0 down | Aug 9, 2022 | $7.67M |
| Mar 31, 2022 | -$0.33 | $0.10 | -$0.31 - $0.51 | -430.00% | Miss | N/A | 2 | 0 up, 0 down | May 10, 2022 | $5.33M |
| Dec 31, 2021 | -$0.38 | -$0.31 | -$0.34 - -$0.25 | -22.58% | Miss | N/A | 3 | 0 up, 0 down | Mar 23, 2022 | $2.53M |
| Sep 30, 2021 | -$0.28 | -$0.28 | -$0.28 - -$0.28 | 0.00% | In line | N/A | 3 | N/A | Nov 10, 2021 | $2.53M |
| Jun 30, 2021 | -$0.31 | -$0.24 | -$0.25 - -$0.22 | -29.17% | Miss | N/A | 3 | N/A | Aug 13, 2021 | $2.55M |
| Mar 31, 2021 | -$0.23 | -$0.23 | N/A | 0.00% | In line | N/A | N/A | N/A | Apr 16, 2021 | $2.56M |
| Dec 31, 2020 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 3, 2021 | $2.69M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.48, after -$1.66 the year before. It was -$0.25 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.48 | N/A |
| Dec 31, 2024 | -$1.66 | N/A |
| Dec 31, 2023 | -$1.57 | N/A |
| Dec 31, 2022 | -$1.36 | N/A |
| Dec 31, 2021 | -$1.20 | N/A |
| Dec 31, 2020 | -$0.25 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 13,000 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 13,304 | 9 | |
| 2026Q2 | Jun 30, 2026 | 7,527 | 4 | |
| 2026Q1 | Mar 31, 2026 | 6,709 | 3 | |
| 2025Q4 | Dec 31, 2025 | 4,308 | 3 | |
| 2025Q3 | Sep 30, 2025 | 6,584 | 3 | |
| 2025Q2 | Jun 30, 2025 | 4,871 | 3 | |
| 2025Q1 | Mar 31, 2025 | 4,122 | 3 | |
| 2024Q4 | Dec 31, 2024 | 5,806 | 3 |
2026Q3 Earnings Call
Opening remarks
Najat Khan CEO Good morning, everyone, and thank you for joining Recursion's Third Quarter Earnings Call. We're hosting earnings live from the CGA-IGC Annual Meeting in Denver. Today, we'll share the new FAP data that was presented yesterday at CGA by Dr. Lisa Boardman, along with updates in our oncology program, REC-1245, and progress across our partnerships. Before we get into the data, I want to start with the philosophy behind what we're building. To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover novel biology, design differentiated molecules against challenging targets, and generate clinical evidence that matters for patients. That is what we're building at Recursion. The higher bar we set for ourselves is repeatability. Not one target, not one molecule, or one clinical result, but the ability to do this across programs again and again. Let me show you the progress we're making. Let me start with what we're seeing in patients. We now have positive clinical data from two first-in-class programs. With REC-4881 in FAP, we saw deep reductions in polyp burden that persisted off treatment. Now we're also seeing activity across the GI tract and reduction of larger high-risk polyps. We'll walk you through some of that data today. With REC-1245, we've seen partial responses in heavily pretreated cancer patients, two confirmed and one unconfirmed PR. In that program, our AI platform guided all three decisions, from biological insight on which target to pursue, how to design the molecule, and which patients to study. If you take a step back to molecule design, Sanofi recently optioned a potential first-in-class oral I&I candidate. The chemistry challenge behind that was to design a single molecule that could inhibit two targets. When we talk about novel causal biology, we use the data that we have generated to build proprietary maps of biology and identify targets that may be driving disease. Genentech has now advanced the first neuroscience target from those maps, and we're working together on small molecules against it. That's the repeatability we're starting to see: the same engine uncovering novel targets, producing new molecules, and generating evidence in patients. Behind the progress you just saw is one AI platform that connects biology, chemistry, and the clinic. We draw on more than 50 petabytes of proprietary data to make decisions about which targets to pursue, which molecules to design, and which patients to study. What makes our approach repeatable is how we learn.
Frequently Asked Questions About RXRX
When is Recursion Pharmaceuticals's next earnings date?
Recursion Pharmaceuticals's next earnings report is expected for Feb 23, 2027.
Did RXRX beat earnings estimates last quarter?
Yes. Recursion Pharmaceuticals reported EPS of -$0.22 for the quarter ended Sep 30, 2026, above the -$0.24 estimate, a 8.33% surprise.
What EPS do analysts expect from RXRX next quarter?
The consensus EPS estimate for Recursion Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.22 from 9 analysts, with estimates from -$0.23 to -$0.21.
How often does RXRX beat earnings estimates?
Recursion Pharmaceuticals beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +1.23%.
RXRX pages: Overview, Earnings, Forecast, Financials, Competitors